No Data
No Data
Zhejiang Cheng Yi Pharmaceutical (603811.SH): First repurchase of 0.73% of the company's shares.
On October 8, Gelonhui announced that on October 8, 2024, Zhejiang Cheng Yi Pharmaceutical (603811.SH) publicly disclosed that the company repurchased 2,403,004 shares of the company for the first time through centralized bidding trading, accounting for 0.73% of the company's current total share capital. The highest purchase price was 8.36 yuan/share and the lowest purchase price was 8.03 yuan/share. The total amount paid was 19,786,231 yuan (excluding transaction fees such as commissions).
Zhejiang Cheng Yi Pharmaceutical (603811.SH) has obtained the pharmaceutical registration certificate for Levocarnitine Injection.
Zhejiang Cheng Yi Pharmaceutical (603811.SH) announced on September 9th that it has recently received the approval and issuance of the Drug Registration Certificate for Levocarnitine Injection by the National Medical Products Administration. This product is suitable for a series of complications that occur in chronic kidney failure patients undergoing long-term hemodialysis due to secondary carnitine deficiency, which are clinically manifested as cardiomyopathy, skeletal muscle disease, arrhythmia, hyperlipidemia, as well as hypotension and muscle spasms during dialysis.
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.'s 2024 semi-annual report.
Summary of the 2024 interim report of Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
Zhejiang Cheng Yi Pharmaceutical (603811.SH): The net income in the first half of the year was 76.4655 million yuan, a year-on-year decrease of 15.60%.
Zhejiang Cheng Yi Pharmaceutical (603811.SH) released its 2024 interim report on August 20. During the reporting period, revenue was CNY 0.356 billion, a year-on-year increase of 10.89%, the net income attributable to shareholders of listed companies was CNY 76.4655 million, a year-on-year decrease of 15.60%, the net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was CNY 72.0779 million, a year-on-year decrease of 18.15%, and the basic earnings per share was CNY 0.23. The reason for the increase in revenue was mainly due to the different degrees of growth in sales of joint and vitamin products. Net income attributable to shareholders of listed companies.
Zhejiang Cheng Yi Pharmaceutical (603811.SH): The controlling shareholder and concerted action parties have completed the shareholding of 1.08%, costing 26.9997 million yuan.
Zhejiang Cheng Yi Pharmaceutical (603811.SH) announced that from February 22, 2024 to August 9, 2024, ...
No Data
No Data